specifically examined patients with MASLD cirrhosis and type 2 diabetes, finding that GLP-1 receptor agonist initiation was linked to reduced risk of unfavorable liver outcomes including hepatic decompensation events and mortality from any cause (aHR: 0.78, 95%CI: 0.68-0.90) relative to non-users, suggesting potential benefits even in advanced liver disease populations [58]
Its just to get my body in the right place to start throwing, he said
Previous studies have revealed that GP-17 offers protection from myocardial I/R injury through the suppression of ER stress-related protein expression, including GRP78 and CHOP, thus reducing ER stress (Yu et al., 2021
For a more detailed overview of the research, see this article
on the contrary, the relative risk of developing major adverse cardiovascular events (MACE) was significantly reduced by about 13%